Targeting the vitamin D endocrine system (VDES) for the management of inflammatory and malignant skin diseases: An historical view and outlook

Reviews in Endocrine and Metabolic Disorders

Volumn 17, Issue 3, 2016, Pages 405-417

  Reichrath, Jörg ^a   Zouboulis, Christos C ^b   Vogt, Thomas ^a   Holick, Michael F ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b DESSAU MEDICAL CENTER   (Germany)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Melanoma; Psoriasis; Skin; Skin cancer; Skin diseases; Vitamin D; Vitamin D endocrine system; Vitamin D receptor

Indexed keywords

CALCITRIOL; PROTEIN P53; VITAMIN D DERIVATIVE; CALCITRIOL RECEPTOR; VITAMIN D;

ACNE; BIOLOGICAL ACTIVITY; CANCER PREVENTION; CONTROLLED CLINICAL TRIAL (TOPIC); DERMATITIS; ENDOCRINE SYSTEM; HUMAN; ICHTHYOSIS; MELANOMA; NON MELANOMA SKIN CANCER; NONHUMAN; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROSACEA; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN; SKIN CANCER; SKIN DISEASE; SKIN INJURY; WOUND HEALING; INFLAMMATION; METABOLISM; SKIN DISEASES; SKIN NEOPLASMS;

ENDOCRINE SYSTEM; HUMANS; INFLAMMATION; RECEPTORS, CALCITRIOL; SKIN; SKIN DISEASES; SKIN NEOPLASMS; VITAMIN D;

EID: 84979248389     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-016-9353-4     Document Type: Review

References (93)

1. Mason RS, Reichrath J. Sunlight vitamin D and skin cancer. Anti Cancer Agents Med Chem. 2013;13:83–97. doi:10.2174/187152013804487272.
2. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81. doi:10.1056/NEJMra070553.
3. Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007;16:618–25.
4. Saternus R, Pilz S, Gräber S, Kleber M, März W, Vogt T, et al. A closer look at evolution: variants (SNPs) of genes involved in skin pigmentation, including EXOC2, TYR, TYRP1, and DCT, are associated with 25(OH)D serum concentration. Endocrinology. 2015;156:39–47.
5. Rossberg W, Saternus R, Wagenpfeil S, Kleber M, März W, Vogt Th, et al. Skin pigmentation, cutaneous vitamin D synthesis and evolution: variants of genes (SNPs) involved in skin pigmentation are associated with 25(OH)D serum concentration. Anticancer Res. 2016.
6. Matsumoto K, Azuma Y, Kiyoki M, Okumura H, Hashimoto K, Yoshikawa K. Involvement of endogenously produced 1,25-dihydroxyvitamin D-3 in the growth and differentiation of human keratinocytes. Biochim Biophys Acta. 1991;1092:311–8.
7. 3) on vitamin D photosynthesis in patients with psoriasis. J Am Acad Dermatol. 1996;35:690–5.
8. 3 in an in vitro human skin equivalent model. J Invest Dermatol. 2001;117:1179–85.
9. 3 (calcitriol) in human skin by microdialysis. Arch Dermatol Res. 2003;295:24–8.
10. Vatieghem K, Dehaes P, Bouillon R, Segaert S. Cultured fibroblasts produce non-active vitamin D metabolites that can be activated by cultured keratinocytes. In: Abstracts Twelfth Workshop on Vitamin D, July 6-10, 2003, Maastricht, The Netherlands, page 27.
11. 3 increases intracellular calcium in human keratinocytes. Br J Dermatol. 1991;124:12230–5.
12. 3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem. 1990;1:81–7.
13. Reichrath J, Reichrath S, Heyne K, Vogt T, Roemer K. Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling. Front Physiol. 2014;5:166. doi:10.3389/fphys.2014.00166.
14. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int. 2013;92(2):77–98. doi:10.1007/s00223-012-9619-0.
15. Baker AR, Mc Donnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A. 1988;85:3294–8.
16. Yu VC, Deisert C, Andersen B, Holloway JM, Devary OV, Näär AM, et al. RXRβ: a coregulator that enhances binding of retinoic acid, thyroid hormone and vitamin D receptors to their cognate response elements. Cell. 1991;67:1251–66.
17. Heyne K, Heil TC, Bette B, Reichrath J, Roemer K. MDM2 binds and inhibits vitamin D receptor. Cell Cycle. 2015;14(13):2003–10. doi:10.1080/15384101.2015.1044176.
18. 3 receptors in normal and psoriatic skin. J Invest Dermatol. 1991;97:230–9.
19. Reichrath J, Münssinger T, Kerber A, Rochette-Egly C, Chambon P, Bahmer FA, et al. In situ detection of retinoid-X receptor expression in normal and psoriatic human skin. Br J Dermatol. 1995;133:168–75.
20. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown under serum-free conditions. J Invest Dermatol. 1986;86:709–14.
21. 3. Endocrinol. 1983;113:1950–7.
22. 3. Biochem Pharmacol. 1995;49:621–4.
23. Rigby WFC. The immunobiology of vitamin D. Immunol Today. 1988;9:54–8.
24. Texereau M, Viac J. Vitamin D, immune system and skin. Eur J Dermatol. 1992;2:258–64.
25. Gombard HF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067–77.
26. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909–12.
27. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770–3.
28. 3, alpha-melanocyte stimulating hormone, and beta-estradiol. J Invest Dermatol. 1988;91:593–8.
29. Krämer C, Seltmann H, Seifert M, Tilgen W, Zouboulis CC, Reichrath J. Characterization of the vitamin D endocrine system in human sebocytes in vitro. J Steroid Biochem Mol Biol. 2009;113(1-2):9–16.
30. 3. Proc Natl Acad Sci U S A. 1985;82:5409–12.
31. 3. Med J Osaka Univ. 1985;35:3–4. 51-4.
32. 3 treatment in psoriasis vulgaris. Br J Dermatol. 1986;115:421–9.
33. 3 and parathyroid hormone related peptide in dermatology: a new perspective. J Invest Dermatol (Symp Proc). 1996;1:1–9.
34. 3) for the treatment of psoriasis. Br J Dermatol. 1996;134:238–46.
35. 3 analogue (MC 903) in a double-blind study. Br J Dermatol. 1988;119:223–30.
36. 3 in psoriasis. Br J Dermatol. 1989;120:661–4.
37. Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol. 1999;141(2):274–8.
38. 3 for the treatment of plaque psoriasis: a pilot study. Br J Dermatol. 2001;144(3):500–6.
39. Miyachi Y, Ohkawara A, Ohkido M, Harada S, Tamaki K, Nakagawa H, et al. Long-term safety and efficacy of high-concentration (20 microg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol. 2002;12(5):463–8.
40. van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Honigsmann H, Marks R, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol. 2002;146(3):414–22.
41. Kragballe K, Gjertsen BT, de Hoop D, Karlsmark T, van de Kerhof PCM, Larko O, et al. Double-blind right/left comparison of calcipotriol and betametasone valerate in treatment of psoriasis vulgaris. Lancet. 1991;337:193–6.
42. 3 analogues: a novel class of potent regulators of cell growth and immune response. Biochem Pharmacol. 1991;42:1569–75.
43. Queille-Roussel C, Duteil L, Parneix-Spake A, Arsonnaud S, Rizova E. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergic contact sensitization and phototoxicity. Eur J Dermatol. 2001;11(3):219–24.
44. 3) for the treatment of psoriasis. Br J Dermatol. 1996;134:1070–8.
45. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol. 1997;36:19–28.
46. 3. J Invest Dermatol. 1996;106:637–41.
47. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, et al. Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associaated p300 protein in terminal differentiation. Proc Natl Acad Sci U S A. 1995;92:5451–5.
48. Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res. 2007;299(10):487–91.
49. Okita H, Ohtsuka T, Yamakage A, Yamazaki S. Polymorphism of the vitamin D(3) receptor in patients with psoriasis. Arch Dermatol Res. 2002;294(4):159–62.
50. Park BS, Park JS, Lee DY, Youn JI, Kim IG. Vitamin D receptor polymorphism is associated with psoriasis. J Investig Dermatol. 1999;112(1):113–6.
51. Saeki H, Asano N, Tsunemi Y, Takekoshi T, Kishimoto M, Mitsui H, et al. Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris. J Dermatol Sci. 2002;30(2):167–71.
52. Lee DY, Park BS, Choi KH, Jeon JH, Cho KH, Song KY, et al. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Arch Dermatol Res. 2002;294(1-2):1–5.
53. Kontula K, Välimäki S, Kainulainen K, Viitanen AM, Keski-Oja J. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br J Dermatol. 1997;136:147–8.
54. Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol. 1998;110:301–2.
55. Colin EM, Weel AEAM, Uitterlinden AG, Buurman CJ, Birkenhäger JC, Pols HAP, et al. Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25-dihydroxyvitamin D3. Clin Endocrinol. 2000;52:211–6.
56. Staberg B, Oxholm A, Klemp P, Christiansen C. Abnormal vitamin D metabolism in patients with psoriasis. Acta Derm Venereol. 1987;67(1):65–8.
57. Stewart AF, Battaglini-Sabetta J, Millstone L. Hypocalcemia-induced pustular psoriasis of von Zumbusch. New experience with an old syndrome. Ann Intern Med. 1984;100(5):677–80.
58. Stone OJ. Chloroquine, ground substance, aggravation of psoriasis. Int J Dermatol. 1985;24(8):539.
59. Lucker GP, van de Kerkhof PC, van Dijk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyosis. Br J Dermatol. 1994;131:546–50.
60. Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. Dermatology. 2001;202(2):116–8.
61. 3: evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol (Stockh). 1993;73:449–51.
62. Garnier G. Vitamin D2 in treatment of acne conglobata. Arch Belg Dermatol Syphiligr. 1964;20:105–8.
63. Cerri B. Attempted therapy for lupus vulgaris and juvenile acne with provitamins of the D group. Minerva Dermatol. 1952;27(3):53–7.
64. Maynard MT. Vitamin D in acne: a comparison with X-ray treatment. Cal West Med. 1938;49(2):127–32.
65. Agak GW, Qin M, Nobe J, Kim MH, Krutzik SR, Tristan GR, et al. Propionibacterium acnes induces an IL-17 response in acne vulgaris that is regulated by vitamin A and vitamin D. J Invest Dermatol. 2014;134(2):366–73. doi:10.1038/jid.2013.334.
66. Hayashi N, Watanabe H, Yasukawa H, Uratsuji H, Kanazawa H, Ishimaru M, et al. Comedolytic effect of topically applied active vitamin D3 analogue on pseudocomedones in the rhino mouse. Br J Dermatol. 2006;155(5):895–901.
67. 3 and more. How rosacea may develop. Hautarzt. 2011;62(11):815–9. doi:10.1007/s00105-011-2142-9.
68. Heilborn JD, Weber G, Grönberg A, Dieterich. Topical treatment with the vitamin D analogue calcipotriol enhances the upregulation of the antimicrobial protein hCAP18/LL-37 during wounding in human skin in vivo. Exp Dermatol. 2009.
69. Reichrath J, Holick MF. Clinical utility of 1,25-dihydroxyvitamin D3 and its analogs for the treatment of psoriasis and other skin diseases. In: Holick MF, editor. Vitamin D. Physiology, molecular biology and clinical applications. New Jersey: Humana Press Totowa; 1999. p. 357–74.
70. Carrozzo AM, Gatti S, Ferranti G, Primavera G, Vidolin AP, Nini G. Calcipotriol treatment of confluent and reticulated papillomatosis (Gougerot-Carteau syndrome). JEADV. 2000;14:131–3.
71. Bikle DD. The vitamin D receptor: a tumor suppressor in skin. Discov Med. 2011;11(56):7–17.
72. 3 receptors in basal cell carcinomas. Am J Pathol. 1999;155(2):583–9.
73. Reichrath J, Rafi L, Rech M, Mitschele T, Meineke V, Gärtner BC, et al. Analysis of the vitamin D system in cutaneous squamous cell carcinomas (SCC). J Cutan Pathol. 2004;31(3):224–31.
74. Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gärtner BC, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Investig. 2004;84(6):693–702.
75. Uhmann A, Niemann H, Lammering B, Henkel C, Heß I, Nitzki F, et al. Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of Hedgehog (Hh) signaling and induction of vitamin D receptor signaling and differentiation. Mol Cancer Ther. 2011;10(11):2179–88.
76. Biijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched dependent (pro)vitamin D3 secretion. PLoS Biol. 2006;4:e232.
77. Köstner K, Denzer N, Müller CSL, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a meta-analysis of the literature. Anticancer Res. 2009;29:3511–36.
78. Denzer N, Vogt T, Reichrath J. Vitamin D receptor (VDR) polymorphisms and skin cancer: a systematic review. Dermatoendocrinol. 2011;3(3):205–10.
79. Köstner K, Denzer N, Koreng M, Reichrath S, Gräber S, Klein R, et al. Association of genetic variants of the vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): a pilot study in a German population. Anticancer Res. 2012;32(1):327–33.
80. Ramachandran S, Fryer AA, Lovatt TJ, Smith AG, Lear JT, Jones PW, et al. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. Cancer Lett. 2003;189(2):175–81.
81. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis. 2007;28(2):390–7.
82. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol. 2002;147(2):197–213.
83. Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther. 2007;6(1):48–55.
84. Essa S, Reichrath S, Mahlknecht U, Montenarh M, Vogt T, Reichrath J. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines. Anticancer Res. 2012;32(1):383–9.
85. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients. 2000.
86. Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer. 2004;91(4):765–70.
87. Mandelcorn-Monson R, Marrett L, Kricker A, Armstrong BK, Orlow I, Goumas C, et al. Sun exposure, vitamin D receptor polymorphisms FokI and BsmI and risk of multiple primary melanoma. Cancer Epidemiol. 2011;35(6):e105–10.
88. Mocellin S, Nitti D. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer. 2008;113(9):2398–407.
89. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27(32):5439–44.
90. Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res. 2009;29(9):3669–74.
91. Bade B, Zdebik A, Wagenpfeil S, Gräber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS One. 2014;9(12):e112863. doi:10.1371/journal.pone.0112863.
92. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, et al. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol. 2016.
93. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women’s health initiative randomized controlled trial. J Clin Oncol. 2011;29(22):3078–84.